TGIF transcription factors repress acetyl CoA metabolic gene expression and promote intestinal tumor growth

Anant Shah,¹ Tiffany A. Melhuish,¹ Todd E. Fox,² Henry F. Frierson Jr,³ and David Wotton¹

¹Department of Biochemistry and Molecular Genetics, Center for Cell Signaling, University of Virginia, Charlottesville, Virginia 22908, USA; ²Department of Pharmacology, ³Department of Pathology, University of Virginia, Charlottesville, Virginia 22908, USA

Tgif1 (thymine–guanine-interacting factor 1) and **Tgif2** repress gene expression by binding directly to DNA or interacting with transforming growth factor (TGF) β -responsive SMADs. Tgifs are essential for embryogenesis and may function in tumor progression. By analyzing both gain and loss of Tgif function in a well-established mouse model of intestinal cancer, we show that Tgifs promote adenoma growth in the context of mutant *Apc* (*adenomatous polyposis coli*). Despite the tumor-suppressive role of TGF β signaling, transcriptome profiling of colon tumors suggests minimal effect of Tgifs on the TGF β pathway. Instead, it appears that Tgifs, which are up-regulated in *Apc* mutant colon tumors, contribute to reprogramming metabolic gene expression. Integrating gene expression data from colon tumors with other gene expression and chromatin-binding data identifies a set of direct Tgif target genes encoding proteins involved in acetyl CoA and pyruvate metabolism. Analysis of both tumor and nontumor tissues indicates that these genes are targets of Tgif repression in multiple settings, suggesting that this is a core Tgif function. We propose that Tgifs play an important role in regulating basic energy metabolism in normal cells, and that this function of Tgifs is amplified in some cancers.

[**Keywords:** TGF β ; Tgif; Wnt; cancer; colorectal cancer; gene expression; metabolism; repressor]

Supplemental material is available for this article.

Received August 24, 2018; revised version accepted January 24, 2019.

Colorectal cancer (CRC) is among the most frequently diagnosed cancers and is the third leading cause of cancer deaths in adults (Miller et al. 2016). The *adenomatous polyposis coli* (*APC*) gene, which is mutated in up to 80% of sporadic CRC (Kinzler and Vogelstein 1996; Segditsas and Tomlinson 2006), encodes a scaffold-like protein that assembles a complex of proteins including β -catenin, Axins, and GSK3 β (Sancho et al. 2004; Clevers and Nusse 2012). In the absence of Wnt ligands, β -catenin is phosphorylated and degraded. Wnt signaling prevents phosphorylation and destruction of β -catenin, allowing it to accumulate and activate gene expression. Mutation or deletion of *APC* results in constitutive β -catenin-dependent gene activation, primarily via interactions with the TCF/LEF transcription factors (Polakis 1995; Sancho et al. 2004). Inactivation of one allele of the mouse *Apc* gene by germ-line mutation (Moser et al. 1990; Fodde et al. 1994; Oshima et al. 1995) or by CRE-mediated excision of a loxP-flanked exon (Shibata et al. 1997; Colnot et al. 2004; Hinoi et al. 2007) causes multiple adenomas, due to sporadic inactivation of the remaining allele.

In response to transforming growth factor β (TGF β) ligands, the type I and type II receptors form a complex, re-

sulting in phosphorylation and activation of the SMAD transcription factors (Feng and Derynck 2005; Massagué et al. 2005). TGF β , Activin, or Nodal signaling results primarily in activation of SMAD2 and SMAD3, which, in association with SMAD4, accumulate in the nucleus to activate gene expression. TGF β signaling is tumor suppressive in many cancers, in part due to the antiproliferative effects of the pathway (Levy and Hill 2006; Massagué 2008). Inactivating mutations in the *TGFBR2* gene, encoding the type II receptor, are found in around 25% of CRC (Markowitz et al. 1995; Grady et al. 1999). Loss of heterozygosity of a region of chromosome 18 that includes both *SMAD2* and *SMAD4* is seen in almost 70% of CRC but is less frequently observed in colorectal adenomas (Vogelstein et al. 1988). Conditional inactivation of the mouse *Tgfbr2* gene in combination with an *Apc* mutation results in progression to invasive adenocarcinoma, whereas homozygous *Tgfbr2* deletion alone in the intestine has no effect (Muñoz et al. 2006).

TGIF1 (thymine–guanine-interacting factor) and the closely related TGIF2 are homeodomain transcription

Corresponding author: dw2p@virginia.edu

Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.320127.118>.

© 2019 Shah et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

factors that are members of the TALE (three-amino-acid loop extension) superfamily (Bertolino et al. 1995; Melhuish et al. 2001; Hyman et al. 2003). Other TALE homeodomain proteins include the Meis and Pbx families that activate gene expression (Bürglin and Affolter 2016). In contrast, TGIF1 and TGIF2 are transcriptional repressors that interact with multiple general corepressors, including mSin3 and histone deacetylases (Wotton et al. 1999a; Melhuish et al. 2001). In addition, TGIF1 recruits CtBP1/2 corepressors via a conserved interaction motif (Melhuish and Wotton 2000). Tgifs limit the response to TGF β signaling by recruiting corepressors to the SMAD transcription factors (Wotton et al. 1999a; Melhuish et al. 2001). In addition to SMAD interaction, other mechanisms for TGF β pathway inhibition have been suggested, including promoting SMAD2 ubiquitylation and degradation or preventing SMAD2 phosphorylation in response to TGF β signaling (Seo et al. 2004, 2006). Loss-of-function *TGIF1* mutations are associated with holoprosencephaly (HPE), a severe genetic disease affecting forebrain development (Wotton and Taniguchi 2018). Mouse models of *Tgif1* and *Tgif2* loss of function suggest they play a redundant, but essential role in early embryogenesis (Powers et al. 2010). Conditional mutants survive to mid-gestation with multiple developmental abnormalities, including HPE (Taniguchi et al. 2012, 2017).

Although developmental defects in embryos lacking *Tgif1* and *Tgif2* can be partly rescued by reducing TGF β family signaling through mutation of *Nodal* (Powers et al. 2010; Taniguchi et al. 2012, 2017), transcriptome profiling of early embryos or primary mouse embryo fibroblasts (MEFs) lacking Tgifs suggests that the majority of gene expression changes are unlikely to be due to altered TGF β family signaling (Zerlanko et al. 2012; Anderson et al. 2017). TGIF1 was first identified by its ability to bind a retinoid response element of the *Rbp2* gene and reduce activation by RXR nuclear receptors (Bertolino et al. 1995). TGIFs can bind directly to DNA and repress transcription via a well-defined consensus site, cTGTCaA, where the central five bases are most important (Bertolino et al. 1995; Wotton et al. 1999b). Direct repression via this consensus site has been shown for a small number of *Tgif* target genes (Anderson et al. 2017; Taniguchi et al. 2017). Recent genome-wide analysis identified a large number of potential *Tgif1*-binding sites, with enrichment for the known TGIF consensus element (Lee et al. 2015).

Increased *Tgif* levels have been implicated in ovarian, esophageal, and lung cancer among others (Imoto et al. 2000; Nakakuki et al. 2002; Wang et al. 2015). *Tgif1* promoted breast cancer progression in a mouse model, independent of effects on TGF β signaling (Zhang et al. 2015). The *TGIF1* gene was shown to be a direct β -catenin/TCF transcriptional target that is activated by Wnt/ β -catenin signaling, and the possibility that TGIF1 sequesters Axins to activate Wnt/ β -catenin signaling was also suggested as a mechanism to explain its protumorigenic function (Zhang et al. 2015). Recent work with human CRC cell lines suggested a role for TGIF1 in CRC progression and also implicated TGIF1 in controlling the output of the

Wnt/ β -catenin pathway, although this appeared to be independent of effects on Axins (Wang et al. 2017). Thus, Tgifs can promote tumorigenesis, but questions regarding mechanisms of action and potential overlapping roles of *Tgif1* and *Tgif2* remain.

We used genetically engineered mouse models to address the function of Tgifs in intestinal epithelial neoplasms and to identify downstream *Tgif* target genes. Overexpression of TGIF1 in intestinal epithelial cells increased the size and number of adenomas in the small intestine, and deletion of *Tgif1* and *Tgif2* reduced tumor size in both the small intestine and colon. Transcriptional profiling of colon tumors from these mice revealed little effect of Tgifs on either Wnt/ β -catenin or TGF β signaling. Instead, we found that deleting Tgifs from colon tumors caused changes in expression of genes affecting multiple metabolic pathways. Integrating these data with additional gene expression profiling results suggests that Tgifs play a fundamental role in regulating energy metabolism, and may contribute to the reprogramming of metabolic gene expression that occurs in CRC.

Results

Increased Tgif expression in colorectal tumors

Analysis of TCGA colorectal data showed elevated *TGIF1* and *TGIF2* in adenocarcinomas (Fig. 1A). Similar results were seen with additional CRC data sets, and in comparison of paired tumor and normal samples, *TGIF1* expression was higher in tumors in all cases (Supplemental Fig. S1). Mouse models of intestinal cancer, based on genetic alterations found in human cancers or treatment with chemical carcinogens, have been analyzed by gene expression array (Kaiser et al. 2007). In these analyses, *Tgif1* expression was significantly higher in the azoxymethane (AOM) and *Apc* mutant models but not in one based on inactivation of *Smad3*, a component of the TGF β signaling pathway (Supplemental Fig. S2A). Similar results were found with *Tgif2* expression in this data set, although the signal in the AOM samples was too variable to reach statistical significance.

To test expression of *Tgifs* in *Apc* mutant mouse colon tumors, we combined a Villin-Cre transgene with a loxP-flanked allele of *Apc* isolated from normal colon and colon tumors at 12 wk of age and analyzed gene expression by qRT-PCR. We observed a significant increase in expression of both *Tgif1* and *Tgif2* in colon tumors compared with normal tissue (Fig. 1B). Western blot analysis of similar 12-wk tumors showed increased *Tgif1* protein expression in tumors compared with normal (Fig. 1C, note that *Tgif1* migrates as a doublet due to MAPK mediated phosphorylation; Lo et al. 2001). An increase in *Tgif1* expression in small intestine tumors compared with normal tissue was also observed (Fig. 1D). We also analyzed tumors in which *Tgif1* was deleted specifically from epithelial cells, by including homozygous conditional loxP-flanked alleles of *Tgif1*. Little or no *Tgif1* signal was detectable in these samples, suggesting that the majority of *Tgif1* present in normal colon and its increase in tumors

Figure 1. Increased expression of Tgifs in intestine tumors. (A) Log₂ median centered expression data for *TGIF1* and *TGIF2* in the TCGA colorectal data set (analysis from Oncomine, with upper and lower quartiles and 10th and 90th percentiles), for normal and the indicated tumor types. *P*-values for comparisons with normal are shown. (B) Relative *Tgif1* and *Tgif2* expression (mean + SD of quadruplicate samples) determined by qRT-PCR, from wild-type (normal) colon or from *Apc* mutant colon tumors. (**) *P* < 0.01; (***) *P* < 0.001; (****) *P* < 0.0001. (C) Expression of *Tgif1* was analyzed by Western blot (with Hsp90 as a loading control) from normal colon (N) and tumor (T) from tissue of the indicated genotypes. (+) Wild type; (r) recombinant allele. (D) *Tgif1* expression from the small intestine (normal or tumor, as in C). (E) Expression of *Tgif1* in normal (N) and tumor (T) tissue from mice of the indicated genotypes is shown by western blot with a *TGIF1*-specific antiserum and HSP90 as a loading control. Note the transgenic *TGIF1* migrates slightly faster than the endogenous mouse *Tgif1*.

were due to expression in the intestinal epithelium (Fig. 1C). In support of this, analysis of *Tgif1* expression in normal intestinal crypts by immunofluorescence (IF) suggests that *Tgif1* is expressed in the majority of epithelial cells within the crypt (Supplemental Fig. S3). Thus, expression

of both *Tgif1* and *Tgif2* is higher in human CRC and in *Apc* mutant intestinal tumors in mice.

Overexpression of *TGIF1* in intestinal epithelium

To test effects of increased *TGIF1* expression in intestine, we generated a transgene in which T7 epitope-tagged human *TGIF1* was expressed from the Villin promoter. Analysis of transgene expression in a panel of tissues by Western blot showed robust expression in the intestine, with no detectable expression in any other tissue examined (Supplemental Fig. S2B). Within the small intestine, we observed readily detectable expression in the proximal, middle, and distal thirds, with much lower expression in the colon and none in nontransgenic tissue (Supplemental Fig. S2C; Parini et al. 2018). To generate mice lacking both *Tgif1* and *Tgif2* in the intestinal epithelium, we used *Vil-Cre* to delete loxP-flanked *Tgif1* (as previously described) and loxP-flanked *Tgif2*, derived from a knockout first allele from EUCOMM. Mice lacking both *Tgifs* from the intestinal epithelium were viable and grossly normal. Similarly, *Vil-TGIF1* transgenic mice were normal and viable to at least 150 d.

To compare expression of the *Vil-TGIF1* transgene with the endogenous *Tgif1* in *Apc* mutant tumors we performed Western blots with a *TGIF1* antiserum that recognizes both human and mouse *Tgif1*. There was an increase in endogenous *Tgif1* expression in regions of the small intestine with tumors, compared with wild-type tissue (Fig. 1E). The levels of expression of transgenic *TGIF1* were similar in both tumor and normal and, while higher than the expression of mouse *Tgif1* in normal tissue, were quite similar to the increased level of endogenous *Tgif1* in tumors (Fig. 1E). The transgenic *TGIF1* migrates more rapidly on SDS-PAGE than mouse *Tgif1*, and it appears that expression of the transgene effectively reduces expression of endogenous *Tgif1*, as evidenced by the almost complete absence of the slower migrating *Tgif1* band in the transgenic samples (Fig. 1E). Thus, *Vil-TGIF1* is overexpressed to a level similar to that of the elevated endogenous expression seen in tumors.

Altered tumor burden in the intestine

To test effects of *Tgifs* on tumorigenesis, we combined conditional alleles of *Tgif1*, both *Tgif1* and *Tgif2*, or the *Vil-TGIF1* transgene with *Vil-Cre* and a heterozygous loxP-flanked *Apc* allele. At 12 wk of age, small intestines were separated into proximal, middle, and distal thirds and opened along the length to identify tumors. Although the number of tumors per animal was quite variable, there was a significant reduction in tumor numbers in mice lacking both *Tgif1* and *Tgif2* and an increase in the *Vil-TGIF1* mice (Fig. 2A). The number of tumors >1.5 mm in diameter was significantly lower in both the *Tgif1* and *Tgif1;Tgif2* mutants (Fig. 2A). The increase in larger tumors in the *TGIF1*-overexpressing mice was highly significant, whereas there were no significant differences in the number of smaller (<1.5-mm) tumors. Histological examination of tumors isolated from animals of all four

Figure 2. Tgif expression promotes intestinal tumorigenesis. (A) The numbers of tumors per animal (at 12 wk) in the small intestine are shown (median, upper, and lower quartiles, 5th and 95th percentiles) for each genotype. Numbers are shown for all tumors and separately for those <1.5 mm or >1.5 mm in diameter. *P*-values for comparison with the *Apc*^{+/+} mice are shown. (B) Number of colon tumors per mouse and tumor volume in mm³ are shown (median, upper, and lower quartiles, 5th and 95th percentiles). *P*-values for comparison with the *Apc*^{+/+} mice are shown. (*) *P* < 0.05; (**) *P* < 0.01; (***) *P* < 0.001. (C) Representative images of hematoxylin and eosin (H&E)-stained colon tumors from the indicated genotypes are shown. Images were captured at 200× magnification.

genotypes revealed no clear differences in tumor morphology (Supplemental Fig. S4A). All tumors examined were adenomas, and we did not observe invasive carcinomas in these animals. Thus, increasing TGIF1 expression to a level similar to that seen in *Apc* mutant tumors enhances adenoma growth, but does not promote transition to invasive adenocarcinoma.

In the middle and distal regions of the small intestine, we observed increased numbers of larger tumors in Vil-TGIF1 mice and a decrease in total tumor numbers in *Tgif1*;*Tgif2* mice driven primarily by changes in the numbers of larger tumors (Supplemental Fig. S4B,C). *Apc* mutant mice lacking only *Tgif1* had an intermediate phenotype between that of the *Apc* and mice lacking both *Tgif1* and *Tgif2*. This was particularly evident when analyzing the proportion of tumors in each mouse that were >1.5 mm in diameter (Supplemental Fig. S4D). Although the *Vil-Cre*;*Apc* model primarily generates tumors in the small intestine, there are also colon tumors in these animals. Comparison of tumor number and size in the colon between *Apc* mice and those lacking *Tgif1* did not reveal any significant differences (Fig. 2B). However, in the *Apc*;*Tgif1*;*Tgif2* mice (referred to here as ATT), average tumor volume was significantly lower, despite the fact that the sizes were quite variable (Fig. 2B). Thus, it appears that further reducing overall *Tgif* levels by deleting *Tgif1* and *Tgif2* enhances the relatively mild effect of deletion of *Tgif1* alone, implying redundant function. As with the SI tu-

mors, there were no clear histological differences between the colon tumors from mice of each genotype (Fig. 2C). Together, these data suggest that *Tgif1* and *Tgif2* contribute to *Apc* mutant intestinal tumorigenesis, and that increasing TGIF1 expression drives adenoma growth.

Transcriptional changes in *Tgif* mutant tumors

To address how increased *Tgif* levels contribute to intestinal tumor growth we performed transcriptome profiling, comparing normal wild-type colon with colon tumors from *Apc* and ATT mice. RNA was isolated from five normal colon samples and from seven tumors from mice of each of the two genotypes from both males and females. The samples from each of the three genotypes clustered separately, although there was considerable spread among the tumors, and the two tumor genotypes clustered closer to each other than to the wild types (Fig. 3A). To identify genes that were differentially expressed, we performed pairwise comparisons using a 0.5 log₂ fold change and an adjusted *P*-value cutoff of <0.01. This identified close to 2000 genes that were differentially expressed between the two tumor genotypes, with 884 being higher in the ATT than in the *Apc* tumors and 1160 with lower expression (Supplemental Table S1). Hierarchical clustering of each of these two gene lists suggested that, among the genes with increased expression in the ATT compared with the *Apc* tumors, a small fraction was also more

among genes that are significantly differently expressed in both the *Apc* to wild type and ATT to *Apc* comparisons (Fig. 3D). However, more genes with higher expression in ATT tumors had reduced expression in *Apc* tumors compared with wild type (124/392; 31.6%) than had higher expression (72/392; 18.4%). Thus, it appears that there is a subset of differentially expressed genes that fit with being Tgif targets, but there is also significant tumor to tumor variability and a larger number of genes that do not fit a simple direct Tgif target model.

Tgifs are well characterized as repressors of TGF β -responsive transcription (Wotton et al. 1999a; Wotton and Taniguchi 2018) and have been suggested to promote Wnt-responsive gene expression (Zhang et al. 2015; Wang et al. 2017). We therefore examined expression of genes that are known targets of these pathways. For a panel of well-characterized TGF β targets (*Smad7*, *Skil*, *Serpine1*, *Cdkn1a*, and *Cdkn2b*) and some additional genes that respond to TGF β in LS1034 CRC cells (Labbé et al. 2007) there was no consistent pattern in expression differences between normal colon and *Apc* tumors, and deletion of Tgifs had minimal effect (Supplemental Fig. S5A). Overlapping gene expression changes in ATT compared with *Apc* tumors with expression array data from mouse *Apc* colon tumors or *Apc* tumors lacking the TGF β type 2 receptor (GSE82133) (Miguchi et al. 2016) revealed minimal overlap (Supplemental Fig. S5B). qRT-PCR analysis of canonical TGF β target genes in a set of ATT and *Apc* colon tumors did not show significant increases in expression in the *Tgif* mutants (Supplemental Fig. S5C).

To examine Wnt signaling we looked at expression of canonical targets of the pathway. These genes were clearly activated in *Apc* tumors compared with wild-type colon but were not further activated by deletion of *Tgifs* (Supplemental Fig. S5D). Comparing a set of β -catenin activated or repressed target genes (Herbst et al. 2014) with our data showed limited overlap with expression differences between ATT and *Apc* tumors, whereas there was clear enrichment for these target genes in the comparison between *Apc* and wild-type tissue (Supplemental Fig. S5E). This was supported by qRT-PCR analysis showing increased expression of *Axin2*, *Lgr5*, and *Lef1* in *Apc* mutant tumors, but no decrease in ATT tumors, as would be expected if *Tgif1* promotes β -catenin-activated gene expression (Supplemental Fig. S5F). Thus, it appears that in the context of colon tumors in mice, Tgifs do not play a major role in regulating either TGF β or Wnt/ β -catenin signaling.

Altered metabolic gene expression in tumors lacking Tgifs

To identify functional groups among the gene expression changes, we performed gene set enrichment analysis (GSEA). Gene sets indicative of epithelial-to-mesenchymal transition (EMT) and KRAS signaling were among the most significantly enriched in the *Apc* compared with ATT tumors (Fig. 3E). Surprisingly, glycolysis was also one of the most significantly enriched gene sets in the *Apc* tumors, and other metabolic signatures were enriched in *Apc* compared with ATT tumors (Fig. 3E). Comparing ATT with *Apc* tumors, one of the most down-regulated glycolytic genes was *Slc2a1*, encoding Glut1, the major glucose transporter in intestine. For most glycolytic enzymes there was a more modest reduction in expression in ATT tumors (Fig. 4A). Examining expression of genes encoding proteins that function to generate glucose from pyruvate revealed that these genes were generally slightly more highly expressed in the ATT tumors. Summing the relative expression for each tumor for a panel of glycolysis or gluconeogenesis-specific genes revealed a

clear separation of *Apc* and ATT tumors, consistent with the GSEA result, despite the relatively minimal changes in expression of most components of these pathways (Fig. 4A).

Since *Slc2a1* was the most down-regulated glycolytic gene in ATT tumors, we examined expression of the Glut1 protein in colon tumors of each genotype by IF. Glut1 was expressed throughout normal colon and *Apc* mutant tumor tissue, with relatively little difference in expression between the two (Fig. 4B). In contrast, there was clearly lower expression of Glut1 in the ATT tumor tissue compared with adjacent normal tissue and with *Apc* mutant tumors (Fig. 4B). We also examined the RNA sequencing (RNA-seq) data for changes in other metabolic pathways by comparing all genes that were significantly differently expressed between *Apc* and ATT tumors to metabolic gene lists from Kyoto Encyclopedia of Genes and Genomes (KEGG). This analysis revealed reduced expression of multiple genes with links to purine and pyrimidine synthesis and amino acid metabolic pathways (Fig. 4C,D). Together, these analyses suggest that loss of Tgifs from *Apc* tumors results in widespread changes in metabolic gene expression.

Increased expression of acetyl CoA metabolism genes in Tgif mutant tumors

The majority of metabolic gene expression changes examined so far are decreases in expression in the absence of Tgifs, suggesting that they are unlikely to be direct Tgif targets. To identify Tgif target genes we overlapped gene expression changes found here with transcriptome profiling from wild-type and conditional *Tgif1*;*Tgif2*-null (conditional double knockout [cdKO]) mouse embryos (Anderson et al. 2017). There was relatively little overlap between these two data sets, but among the genes that changed in both, there was a significant enrichment for genes that increased with deletion of Tgifs from embryos and tumors (Fig. 5A). We reasoned that comparison of these two very different systems might allow us to identify Tgif-regulated genes with higher confidence by ruling out secondary tissue-specific effects. ChIP-seq (chromatin immunoprecipitation [ChIP] combined with high-throughput sequencing) analysis from mouse embryonic stem (ES) cells identified >12,000 potential *Tgif1*-bound regions across the genome (Lee et al. 2015). To enrich for higher-confidence targets, we considered only the top 40% of putative *Tgif1*-bound regions from this analysis, and overlapped this list with genes that were differently expressed in cdKO embryos and tumors lacking Tgifs (Fig. 5B). This revealed a greater overlap with genes that were activated by loss of Tgifs than with genes that had lower expression in the mutants (Fig. 5B,C). Among the genes with increased expression in both cdKO embryos and tumors almost 70% had high confidence ChIP peaks (Fig. 5C).

Analysis of the 125 genes with ChIP-seq peaks and higher expression in both RNA-seq data sets revealed a significant enrichment for a MEIS1 consensus site (which is identical to a TGIF site) associated with these genes, consistent with the idea that they are direct Tgif targets

Figure 4. Altered metabolic gene expression in *Tgif* mutant colon tumors. (**A**) Heat maps are shown indicating fold-change (comparing ATT with Apc tumors) for the glycolytic pathway and for genes involved specifically in the conversion of pyruvate to glucose. The plot to the right shows summed Z-scores for a panel of genes involved only in glycolysis or in gluconeogenesis, plotted as gluconeogenesis versus glycolysis for each tumor. (**B**) IF analysis is shown for Glut1 and β -catenin in colon tumors (T) with adjacent normal tissue (N). Heat maps are shown for all genes in the purine and pyrimidine metabolic pathways (**C**) or amino acid metabolic pathways (**D**) that are significantly differently expressed comparing Apc with ATT tumors.

(Fig. 5D). Propanoate metabolism and acetyl CoA biosynthetic process were the most significantly enriched pathways, and among the 125 gene list were three genes encoding enzymes that synthesize acetyl CoA: *Acss1*, *Acss2*, and *Mlycd*. To place these changes in context, we visualized expression changes for genes encoding a number of enzymes involved in acetyl CoA metabolism as part of a metabolic pathway map. *Acss2* was significantly increased in both *cdKO* embryos and in tumors lacking *Tgifs* and decreased in *Apc* tumors compared with wild-type colon (Fig. 5E). Similarly, the mitochondrial *Acss1* was increased in *Tgif* mutant embryos and tumors and decreased in the *Apc* tumors. Other genes that showed this pattern included *Mlycd*, which encodes a cytosolic enzyme that converts malonyl CoA to acetyl CoA, and *Acat1* which generates acetoacetyl CoA from acetyl CoA in the mitochondria as the first step of ketone synthesis (Fig. 5E). As there was some increase in expression of genes

associated with the early stages of pyruvate metabolism (Fig. 4A) and *Mpc1* and *Pcx* expression was increased in *cdKO* embryos, we also examined some changes in this pathway. *Mpc1* expression showed a similar pattern to the acetyl CoA synthetic genes, as did *Pcx*, although the increase in *Pcx* expression in ATT tumors was not statistically significant (Fig. 5E). This analysis is consistent with the idea that *Tgifs* directly repress multiple genes involved in acetyl CoA metabolism and suggests they may also play a similar function for pyruvate metabolic genes.

IF analysis of colon tissue from *Apc* and ATT mice indicated that *Acss2* expression was reduced in *Apc* mutant tumors compared with adjacent normal colon, and that expression was higher in both normal and tumor tissue in the ATT mice (Fig. 6A). In both small intestine and colon, we observed higher *Acss2* expression, with more evident nuclear localization in the *Tgif1;Tgif2* mice compared with wild type (Supplemental Fig. S6A,B). In support

Figure 5. Identification of putative Tgif target genes. (A) Differentially expressed genes from RNA-seq data from control or *Tgif1*; *Tgif2*-null (cdKO) day 9 mouse embryos (GSE78728) overlapped with genes that are significantly differently expressed in ATT versus Apc tumors. (B) Genes with significantly higher (left) or lower (right) expression in either dataset were overlapped with Tgif1 ChIP-seq data from mouse ES cells (GSE55404). (C) The percentage of genes from each of the indicated overlaps between expression data from embryos and tumors with ChIP-seq peaks is shown. (D) EnrichR analysis of the 125 genes with increased expression in embryos and tumors that also have ChIP-seq peaks is shown. (E) A pathway map for selected genes involved in acetyl CoA and pyruvate metabolism is shown, with mitochondrial and cytoplasmic compartments shown separately. Black arrows indicate metabolic reactions, green arrows translocations, and the dashed arrows links to additional metabolic pathways. For each gene shown (boxed), the three colored squares represent fold changes in comparisons of Apc with wild-type (left), ATT with Apc tumor (center), and cdKO with control embryo (right). Larger boxes indicate significant change (P -adjusted < 0.01). Smaller boxes are not significant at this cutoff.

of this, Western blot of colon tumors indicated higher Acss2 expression in ATT than in Apc tumors, and Pcx expression was also higher in the tumors lacking Tgifs (Fig. 6B). We also analyzed expression of the mitochondrial Acat1. Expression was clearly higher in ATT tumors than in the Apc and in normal small intestine lacking both Tgifs (Fig. 6C; Supplemental Fig. S6C). As with Acss2, expression of Acat1 and Mlycd was increased in ATT compared with Apc colon tumors (Fig. 6D), consistent with the idea that loss of Tgifs in colon tumors results in higher expression of both mitochondrial and nuclear/cytoplasmic metabolic regulators. To further explore this potential Tgif function we analyzed human tumor gene expression data sets. Separating the human The Cancer Genome Atlas (TCGA) CRC data set by *TGIF1* expression levels revealed higher expression of *ACSS1* and *ACSS2* in the quartile of tumors with lowest *TGIF1* expression compared with the upper quartile (Supplemental Fig. S7A). Furthermore, GSEA comparing the upper and lower 10% of tumors from the TCGA PanCancer colon cancer data set

showed enrichment for glycolysis in the *TGIF1* high and enrichment for bile acid and fatty acid metabolism in the lowest 10% by *TGIF1* expression (Supplemental Fig. S7B). Comparison of *ACSS2* levels in multiple CRC data sets suggests that levels are reduced in CRC and that lower expression correlates with poor survival, a pattern that is opposite to that seen for Tgifs (Supplemental Fig. S7C–E). This suggests that similar metabolic gene expression differences are seen in human tumors stratified by *TGIF1* expression levels to those seen in our transcriptome profiling of Apc and ATT tumors.

Direct Tgif-mediated repression of metabolic gene expression

To address the possibility that genes involved in acetyl CoA and pyruvate metabolism are direct Tgif targets in multiple cell types, we tested expression of a panel of these genes by qRT-PCR in normal small intestine and in primary MEFs. All three acetyl CoA synthetic genes

Figure 6. Increased *Acss2* expression in *Tgif* mutant tumors. (A) IF analysis is shown for *Acss2* and β -catenin in colon tumors (T) with adjacent normal (N) tissue from *Apc* mutants and ATT mice. (B) Western blot analysis of colon tumors from *Apc* and ATT mice showing expression of *Acss2* and *Pcx*, together with *Hsp90* and γ -tubulin loading controls. (C) IF analysis is shown for *Acat1* and β -catenin in colon tumors with adjacent normal tissue from *Apc* and ATT mice. (D) Western blot analysis of *Apc* and ATT colon tumors showing expression of *Acat1* and *Mlycd*, together with *Hsp90* and γ -tubulin loading controls. Molecular weight markers are shown for B and D.

and *Acat1* were significantly more highly expressed in *Tgif1*;*Tgif2* null small intestine than in wild-type tissue (Fig. 7A). Similarly, expression of *Pcx* and *Mpc1* was also higher in the mutant. We observed a similar pattern for five of the six genes in primary MEFs (Fig. 7B). *Acss1* expression did not increase in MEFs, but its expression is very low in cultured cells, including primary MEFs. Analysis of metabolite levels in normal small intestine isolated from wild-type mice or those lacking both *Tgifs* suggested that acetate levels were decreased in the absence of *Tgifs* consistent with increased metabolism by higher levels of

Acss1 and *Acss2* (Fig. 7C). Propionate levels were also lower, but did not quite reach significance due to the variability among samples. In contrast, other metabolites were essentially unchanged in *Tgif* mutant small intestine compared with the normal (Fig. 7C). Together with the gene expression changes seen in both embryos and tumors, this is consistent with the possibility that the regulation of acetate metabolism is a conserved core function of *Tgifs*.

We next examined the sequences of the ChIP-seq peaks associated with each of the six genes analyzed in small

Figure 7. *Tgif1* regulation of metabolic gene expression in normal tissue. (A) Expression of the indicated genes was analyzed by qRT-PCR from normal small intestine from wild-type or *cdKO* (*Tgif1*;*Tgif2* *cdKO*) mice. (B) Expression of the same genes was analyzed in wild-type and *cdKO* primary MEFs. Expression is plotted relative to the wild-type mean ($\pm$ SD) of four and three replicates for intestine and MEFs. (*) $P < 0.05$; (**) $P < 0.01$; (***) $P < 0.001$, for comparison with wild type. (C) Analysis of metabolites in normal small intestine from wild-type and *cdKO* mice (mean $\pm$ SEM). Relative levels of the indicated metabolites are shown with the wild-type level for each set to 1. (*) $P < 0.05$ for comparison with wild type.

intestine and primary MEFs. In each case the potential Tgif1-bound region overlapped the transcriptional start site, and for all but *Acss1*, at least two TGIF consensus sites were present (cTGTCa or TGTCAa) (Fig. 8A; Supplemental Fig. S8A). To test Tgif1 recruitment, we performed ChIP-qPCR for the five genes that had ChIP-seq peaks with consensus TGIF sites. For *Mpc1*, we amplified two regions as the predicted peak was quite broad and had consensus sites close to each end (Fig. 8A). In chromatin

from wild-type small intestine, we observed significant enrichment of the putative Tgif1-binding regions from all five genes compared with a negative control region, and similar results were obtained from primary MEFs (Fig. 8B,C). We observed significant enrichment for *Acss2* in the wild-type chromatin compared with chromatin from *Tgif1*;*Tgif2* mutant MEFs, indicating the specificity of this TGIF1 antiserum, as previously demonstrated (Supplemental Fig. S8B; Anderson et al. 2017; Taniguchi

Figure 8. Tgif1-mediated repression of *Acss2* and *Pcx*. (A) The positions of the ChIP-seq peaks, qPCR amplicons, and TGIF consensus sites for each of the five genes tested are shown using University of California at Santa Cruz genome browser views. A 4-kb region, centered on the transcriptional start, is shown for each mouse gene, with similarity to human *below*. (B) Tgif1 binding to each peak region was analyzed by ChIP-qPCR from normal wild-type small intestine. (C) Tgif1 binding in primary MEFs was analyzed by ChIP-qPCR. Chromatin was precipitated with a TGIF1 antiserum or preimmune serum (pre-I). Data is mean + SD of triplicates and is plotted in arbitrary units with the TGIF1 IP for the negative control region (*fbpk3*) set equal to 1. (*) $P < 0.05$; (**) $P < 0.01$; (***) $P < 0.001$, for comparison with *fbpk3*. (D) TGIF1 and TGIF2 were transiently knocked down in HCT116 cells, and expression of the indicated genes analyzed by qRT-PCR. Expression is plotted relative to the nontargeting control knockdown mean (+SD) of 3 replicates. (*) $P < 0.05$; (**) $P < 0.01$, for comparison with control. (E) The *Acss2* and *Pcx* luciferase reporters are shown schematically. Nucleotide positions relative to the transcriptional start site are shown. Black bars are TGIF sites, with the mutant site indicated in white. Gray represents 5'- untranslated sequence, and white is proximal promoter. (F,G) HCT116 cells were transiently transfected with the indicated luciferase reporters together with increasing amounts of a TGIF1 expression vector (or a control plasmid). Luciferase activity is shown (normalized to a Renilla-luc transfection control), with the activity of the *Acss2*-525-luc (F) and the wild-type *Pcx*-368-luc (G) set to 1. (#) $P < 0.01$; (##) $P < 0.001$, for comparison with no TGIF1 transfection. (*) $P < 0.01$; (**) $P < 0.001$; (***) $P < 0.0001$, for comparison with fold-repression of the wild-type reporter.

et al. 2017). Transient knockdown of both *TGIF1* and *TGIF2* in the human CRC cell line, HCT116, resulted in increased expression of all five metabolic genes, consistent with this being a relatively rapid effect of reduced TGIF levels rather than a longer term response to sustained deletion of *Tgif* genes (Fig. 8D). To test direct target gene regulation, we amplified the proximal promoter regions from the *Acss2* and *Pcx* genes and created transcriptional reporters. We chose *Acss2* because it has a cluster of conserved TGIF consensus sites and might be more sensitive to TGIF levels. *Pcx*, which has only a single conserved site in the proximal promoter, facilitated the generation of a simple mutant version of the reporter in which this site was disrupted (Fig. 8E). Since manipulating TGIF levels affected expression of *ACSS2* and *PC* (human *Pcx*) in HCT116 cells, we analyzed *Acss2* and *Pcx* reporter activity by transient transfection into HCT116. Both the *Acss2* and *Pcx* transcriptional reporters were significantly repressed by coexpression of increasing amounts of TGIF1 (Fig. 8F,G). Analysis of a deletion mutant of the *Acss2* reporter lacking all TGIF sites and of the *Pcx* mutant in which the single site was disrupted revealed significantly less repression by TGIF1 than seen with the wild-type reporters. In addition, mutant versions of TGIF1, with single amino acid changes within the homeodomain that prevent DNA binding failed to repress either the *Acss2* or *Pcx* reporter (Supplemental Fig. S8C). These data suggest that DNA binding by TGIF1 is required to repress expression of *Acss2* and *Pcx*, and that this repression is mediated at least in part by conserved consensus TGIF sites. Taken together, these data suggest that Tgifs are direct transcriptional repressors of a set of genes involved in acetyl CoA and pyruvate metabolism.

Discussion

Using an intestinal cancer model as a starting point to analyze TGIF function, we provide evidence that TGIF transcription factors directly regulate genes involved in acetyl CoA metabolism. This function of TGIFs does not appear to be limited to intestinal tumor or normal tissue and may represent a key unexpected function of these transcription factors, independent of the other pathways they are known to regulate.

TGIFs are thought to be oncogenic by limiting the anti-proliferative effects of TGF β signaling. Mutating the *Tgfr2* gene in concert with an *Apc* mutation drives the transition from adenoma to invasive adenocarcinoma (Muñoz et al. 2006). Expression of both *TGIF1* and *TGIF2* is higher in CRC than in normal tissue, and *Tgif* expression is increased in *Apc* mutant intestinal tumors. Such increased *Tgif* levels might be expected to dampen the TGF β response and promote tumor growth. Indeed, we show that *Tgif* expression promotes growth of early adenomas. However, transcriptome profiling of colon tumors revealed almost no overlap with changes in TGF β -responsive gene expression, suggesting that at least in this model Tgifs are not major regulators of TGF β signaling. This is in contrast to the effect of Arkadia (*Rnf111*),

a ubiquitin E3 that promotes TGF β signaling by driving degradation of the Ski and Skil(SnoN) SMAD corepressors. *Rnf111* deletion increased tumor numbers in a mouse colon cancer model, increased Skil expression, and reduced the TGF β response (Sharma et al. 2011). Thus, altered SMAD corepressor levels can affect CRC tumor progression, although it remains possible that other Arkadia substrates contribute.

TGIF1 was proposed to activate Wnt signaling by sequestering Axins, allowing activation of Wnt/ β -catenin target genes (Zhang et al. 2015). In our transcriptome data there is no consistent decrease in expression of canonical Wnt target genes in the absence of Tgifs, as would be predicted by this model. Although it remains possible that any effect on Wnt signaling is a cell type-specific function of Tgif1, our results suggest the Wnt pathway is not a major Tgif1 target in colon tumors. It is possible that Tgif1 promotes β -catenin function, but its effect is masked by the overriding pathway activation caused by *Apc* mutation. However, this still argues against a Tgif effect on tumor promotion via β -catenin in this mouse model. A further link to Wnt signaling is the demonstration that *TGIF1* is directly activated by Wnt/ β -catenin signaling (Zhang et al. 2015). Our data are consistent with this in that *Tgif1* and *Tgif2* expression is increased in *Apc* mutant tumors compared with normal tissue, although we do not know whether *Tgif* genes are β -catenin targets in the intestine. Thus, it appears that Tgifs promote intestinal tumor growth independent of effects on the two most likely pathways.

Genome-wide analysis of Tgif1 binding to chromatin in mouse ES cells suggests that a large part of Tgif function is mediated by direct binding to DNA (Lee et al. 2015). In agreement with this, structural studies show that, unlike many other homeodomain proteins, TGIF1 binds with high specificity and relatively high affinity to its cognate site (Guca et al. 2018). Given the large numbers of gene expression changes observed in tumors lacking Tgifs we attempted to identify higher confidence core Tgif target genes by integrating ChIP-seq data with gene expression data sets from very divergent systems. Surprisingly, pathway analysis of this high confidence gene set identified acetyl CoA metabolism as the most significantly enriched biological process. In addition, analysis of all gene expression changes between *Apc* tumors and *Apc* tumors lacking both Tgifs revealed changes in multiple metabolic pathways, further supporting a role for Tgifs as regulators of metabolism. Increased expression of acetyl CoA metabolic genes is not cell-type specific, occurring in early mouse embryos, primary MEFs, normal small intestine and colon tumors, suggesting that this may be a fundamental, yet unexpected, role of Tgifs. We validated a panel of genes with links to acetyl CoA and pyruvate metabolism as direct Tgif1 targets in normal small intestine and primary MEFs, and demonstrated direct repression of both the *Acss2*- and *Pcx*-proximal promoters by TGIF1. Full repression was dependent on the presence of conserved TGIF consensus sites within the promoters, and was abolished by single amino acid changes in TGIF1 that prevent DNA binding. This is consistent with the notion that the

repression of expression of a subset of metabolic genes is a core Tgif function conserved across multiple cell types that occurs via direct DNA binding to cognate TGIF sites. This further supports recent work suggesting that while Tgifs may limit TGF β -activated gene expression during embryogenesis, much of the Tgif transcriptional function is mediated by direct DNA binding.

Although we observed extensive changes in expression of metabolic genes, relatively few were increased in the Tgif mutant tumors, suggesting that the majority of changes may be indirect effects. Attempting to place potential direct Tgif target genes in context indicates that Tgifs repress anabolic metabolism rather than catabolism. For example, Tgif repression of mitochondrial *Acss1* and *Acat1* would be expected to limit ketone synthesis and the utilization of acetate by both *Acss1* and *Acss2* would be reduced by Tgif-mediated repression. In support of this, we show that in the absence of Tgifs acetate levels are lower in the small intestine, consistent with increased *Acss1* and *Acss2* activity. However, more extensive analyses of metabolic intermediates is clearly required in both normal and tumor tissue to fully validate Tgifs as metabolic regulators. In the absence of Tgifs, anabolic metabolism may favor synthesis of ketones and sterols, and the utilization of pyruvate to generate other metabolic intermediates. This proposed function of Tgifs is reminiscent of the reprogramming of metabolic gene expression that is recognized as one of the hallmarks of cancer. In addition to an increased reliance on glycolysis, termed the Warburg effect (Warburg 1956), there is extensive rewiring of energy metabolism in cancer cells (Hanahan and Weinberg 2011; Pavlova and Thompson 2016).

Recent work suggests that metabolic reprogramming occurs at the adenoma stage of CRC (Satoh et al. 2017), and it appears that this is downstream from activation of oncogenes, such as KRAS or BRAF, and requires high MYC expression (Hutton et al. 2016; Satoh et al. 2017). Our data suggest that Tgifs play a role in regulating metabolic gene expression in both normal and tumor tissues and may mediate part of the metabolic reprogramming that occurs in colon adenomas. A role for TGIF1 in regulating metabolism in human CRC is supported by GSEA comparing colon tumors separated by *TGIF1* expression levels. Interestingly, one of the best-correlated Tgif target metabolic genes in CRC is *ACSS2*, which we show is directly repressed by TGIF1. Several recent studies have linked *ACSS2* expression levels to tumor progression (Comerford et al. 2014; Mashimo et al. 2014; Schug et al. 2015). In contrast to our data, high levels of *ACSS2* expression correlate with poor prognosis in other cancer types, raising the possibility that *ACSS2* may function differently in CRC. This possibility is supported by analysis of CRC gene expression data, suggesting that unlike for other tumor types, a reduction in *ACSS2* expression is observed in CRC and that high expression correlates with better patient prognosis.

One difference that should be noted in this context is the unusual metabolic environment in which colon tumors develop. The metabolic activity of gut bacteria results in high levels of short chain fatty acids, including acetate,

which constitute a major fuel source for colonocytes (Donohoe et al. 2011). This difference compared with most other tissues in the body may impose differing metabolic pressures on developing tumors. For example, a reduction in short chain fatty acid metabolism might facilitate the switch to glycolysis. Therefore, it will be of interest to test functionally whether decreased expression of *ACSS2* or other Tgif targets can promote CRC progression. In addition to direct effects of Tgif expression on genes involved in acetate metabolism, one of the most dramatically affected genes encodes the major glucose transporter, *Glut1*. High Tgif levels appear to favor *Glut1* expression specifically in tumors, which may contribute to a switch away from short chain fatty acid metabolism. However, since expression of *Slc2a1* increased in the absence of Tgifs, this is likely not a direct target for Tgif regulation and may be a response to other alterations in metabolism.

In summary, our data suggest a model in which Tgifs function in multiple cell types to limit expression of a core set of acetyl CoA metabolic genes. In some cancers, including CRC, where Tgif levels increase, this normal Tgif function may be co-opted by the tumor as part of the metabolic reprogramming.

Materials and methods

Mice

All animal procedures were approved by the Animal Care and Use Committee of the University of Virginia, which is fully accredited by the AAALAC. Conditional alleles with loxP flanked exons are referred to here as “f” for loxP flanked, or “r” for recombined (null). Mice were maintained on a C57BL/6 background. Conditional *Apc* mice were from the NCI (01XAA; B6.Cg-*Apc*^{tm2Rak}/Nci), and the Villin-Cre line was from Jax [B6.Cg-Tg(Vill-cre)1000Gum/J; 021504] (Madison et al. 2002). Conditional Tgif2 mice were generated from targeted ES cells from EUCOMM [Tgif2^{tm1a(EUCOMM)Wtsi}]; International Knockout Mouse Consortium (IKMC) project 24492; C57BL/6N ES cells] and crossed to a conditional Tgif1 line that had been back-crossed for six generations to C57BL/6 (Powers et al. 2010). Villin-TGIF1 transgenic mice were generated at the UVA GEMM Core and were back-crossed to C57BL/6 for at least three generations prior to tumor analysis. The human TGIF1 cDNA with an amino-terminal T7 epitope tag was inserted into the Villin promoter plasmid (12.4kbVillin- Δ ATG), which was a gift from Deborah Gumucio (Addgene plasmid 19358; Madison et al. 2002). Germ line transmission was verified by PCR and expression by Western blot.

Tumor analysis, IF, and histology

Tissues were fixed in zinc-formalin, paraffin-embedded, sectioned at 5 μ m and stained with hematoxylin and eosin (H&E) or prepared for immunostaining as described (Hao et al. 2018). Images were captured with 10 $\times$, 20 $\times$, or 40 $\times$ objectives using a Nikon Eclipse NI-U with a DS-QI1 or DS-Ri1 camera and NIS Elements software and adjusted in Adobe Photoshop. For IF, antibodies were as follows: rabbit anti-*Acss2* (Abcam, 66038), mouse anti-TGIF1 (Santa Cruz Biotechnology, SC-17000), rabbit anti-*Acat1* (Proteintech, 16215-1-AP), rabbit anti-*Slc2a1* (Millipore 07-1401), and mouse anti- β -catenin (BD Transduction Labs, 610153).

RNA isolation and qRT-PCR

RNA from snap-frozen tissue was isolated and purified using Absolutely RNA kit (Agilent) and quality-checked by Bioanalyzer. cDNA was generated using SuperScript III (Invitrogen) and analyzed by real-time PCR using a Bio-Rad MyIQ cycler and Sensimix Plus SYBRgreen plus FITC mix (Bioline) with intron-spanning primer pairs selected using Primer3 (<http://frodo.wi.mit.edu>). Expression was normalized to Rpl4 and Cyclophilin using the Δ Ct method.

RNA-seq and analysis

Poly-A RNA-seq libraries generated with Illumina barcodes were sequenced (NextSeq 500 at the University of Virginia Genome Analysis and Technology Core) to at least 25 million single-end 75-bp reads per sample. Data were analyzed using the Galaxy server (<https://usegalaxy.org>). Transcript quantification was performed using Salmon (Patro et al. 2017) to map to the mm10 mouse genome build, and DESeq2 (Love et al. 2014) within the Galaxy site was used for normalizing count data, estimating dispersion, fitting a negative binomial model for each gene, and comparing expression between groups. A cutoff of $\pm 0.5 \log_2$ and an adjusted *P*-value of < 0.01 were considered significant. Enrichment was analyzed with ENRICH (http://amp.pharm.mssm.edu/Enrichr) (Chen et al. 2013; Kuleshov et al. 2016), and heat maps were generated with Heatmapper (<http://www2.heatmapper.ca/expression>) (Babicki et al. 2016). Gene set enrichment was by GSEA software from the Broad Institute (Mootha et al. 2003; Subramanian et al. 2005). RNA-seq data have been deposited at Gene Expression Omnibus (GSE116578).

Western blot and metabolite analysis

Tissues were ground in PBS followed by addition of NP-40 to 1%, lysates were separated by SDS-PAGE and transferred to Immobilon-P (Millipore), and proteins were visualized using ECL (Pierce). Primary antibodies were against Acss2 (Abcam, 66038), TGIF1 (Wotton et al. 1999a), Acat1 (Proteintech, 16215-1-AP), Mlycd (Proteintech, 15265-1-AP), γ -tubulin (Sigma, T6557), and HSP90 (Cell Signaling, 4874). Pcx was detected using Neutravidin-conjugated HRP (Thermo Fisher). Metabolites from normal small intestine (wild type [*N* = 4] or lacking Tgif1 and Tgif2 [*N* = 6]) were analyzed by mass spectrometry: Samples were prepared by derivatization with 3-NPH and analyzed essentially as described (Han et al. 2015). A Waters I-class Acquity chromatography system inline with a Waters TQS mass spectrometer was used for the separation and detection. Metabolite levels were normalized to total protein content in the sample.

ChIP

Chromatin was cross-linked for 20 min in 1% formaldehyde and sonicated to 200–1000 bp using a Branson digital sonifier, with microtip as described (Bjerke et al. 2011). Immunoprecipitation was carried out using 10 μ L of polyclonal TGIF1 antiserum (Wotton et al. 1999a) or preimmune serum. Bound and input fractions were analyzed by qPCR on a Bio-Rad MyIQ cycler using Sensimix Plus SYBR Green plus FITC mix (Bioline).

Cell culture and siRNA knockdown

HCT116 cells were cultured in RPMI (Invitrogen) with 10% fetal bovine serum (Hyclone). Primary MEFs were cultured as described (Zerlanko et al. 2012). For knockdown, cells were plated in six-well plates and transfected with Dharmacon SMARTpool

oligonucleotides against human *TGIF1* and *TGIF2* (as in Anderson et al. 2017), or with a control siGENOME pool using DharmaFECT reagent 1.

DNA constructs and luciferase assays

All luciferase reporter constructs were generated in pGL3 basic (Promega) by PCR from genomic DNA. Cells were transfected with firefly luciferase reporters and a phCMVRLuc control (Promega), with pCMV5 TGIF1 as indicated (2, 6, 18 ng per well), using PEI. The two mutant TGIF1 constructs encode TGIF1 with changes in conserved DNA-binding residues in the homeodomain: either Arg91 altered to methionine (R91M) or Asp88 altered to serine (N88S) (Bjerke et al. 2011). After 48 h, activity was assayed with luciferase assay reagent (Biotium) using a Berthold LB953 luminometer. Results were normalized using Renilla luciferase activity and assayed with 0.09 μ M coelenterazine (Biosynth) as in Hyman-Walsh et al. (2010). Results of replicate transfections are shown (*N* = 3; mean + standard deviation) normalized to the RLuc transfection control.

Acknowledgments

We thank members of the Wotton laboratory for discussions, and Dr. M. Mayo for advice. This work was supported by grants from the National Institute of Neurological Disorders and Stroke (NS077958) and the National Institute of General Medical Sciences (GM099853) to D.W.

Author contributions: A.S., T.A.M., and T.E.F. performed the experiments. A.S., T.A.M., T.E.F., H.F.F., and D.W. analyzed the data. A.S. and D.W. wrote the manuscript.

References

- Anderson AE, Taniguchi K, Hao Y, Melhuish TA, Shah A, Turner SD, Sutherland AE, Wotton D. 2017. Tgif1 and Tgif2 repress expression of the RabGAP Evi5l. *Mol Cell Biol* **37**: e00527–00516. doi:10.1128/MCB.00527-16
- Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, Wishart DS. 2016. Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res* **44**: W147–W153. doi:10.1093/nar/gkw419
- Bertolino E, Reimund B, Wildt-Perinic D, Clerc R. 1995. A novel homeobox protein which recognizes a TGT core and functionally interferes with a retinoid-responsive motif. *J Biol Chem* **270**: 31178–31188. doi:10.1074/jbc.270.52.31178
- Bjerke GA, Hyman-Walsh C, Wotton D. 2011. Cooperative transcriptional activation by Klf4, Meis2, and Pbx1. *Mol Cell Biol* **31**: 3723–3733. doi:10.1128/MCB.01456-10
- Bürglin TR, Affolter M. 2016. Homeodomain proteins: an update. *Chromosoma* **125**: 497–521. doi:10.1007/s00412-015-0543-8
- Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**: 128. doi:10.1186/1471-2105-14-128
- Clevers H, Nusse R. 2012. Wnt/ β -catenin signaling and disease. *Cell* **149**: 1192–1205. doi:10.1016/j.cell.2012.05.012
- Colnot S, Niwa-Kawakita M, Hamard G, Godard C, Le Plenier S, Houbron C, Romagnolo B, Berrebi D, Giovannini M, Perret C. 2004. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. *Lab Invest* **84**: 1619–1630. doi:10.1038/labinvest.3700180

- Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, et al. 2014. Acetate dependence of tumors. *Cell* **159**: 1591–1602. doi:10.1016/j.cell.2014.11.020
- Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, Bultman SJ. 2011. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab* **13**: 517–526. doi:10.1016/j.cmet.2011.02.018
- Feng XH, Derynck R. 2005. Specificity and versatility in TGF- β signaling through Smads. *Annu Rev Cell Dev Biol* **21**: 659–693. doi:10.1146/annurev.cellbio.21.022404.142018
- Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, et al. 1994. A targeted chain-termination mutation in the mouse *Apc* gene results in multiple intestinal tumors. *Proc Natl Acad Sci* **91**: 8969–8973. doi:10.1073/pnas.91.19.8969
- Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Chang J, Kim S-J, Kinzler KW, et al. 1999. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. *Cancer Res* **59**: 320–324.
- Guca E, Suñol D, Ruiz L, Konkol A, Cordero J, Torner C, Aragon E, Martin-Malpartida P, Riera A, Macias MJ. 2018. TGIF1 homeodomain interacts with Smad MH1 domain and represses TGF- β signaling. *Nucleic Acids Res* **46**: 9220–9235. doi:10.1093/nar/gky680
- Han J, Lin K, Sequeira C, Borchers CH. 2015. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. *Anal Chim Acta* **854**: 86–94. doi:10.1016/j.aca.2014.11.015
- Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* **144**: 646–674. doi:10.1016/j.cell.2011.02.013
- Hao Y, Bjerke GA, Pietrzak K, Melhuish TA, Han Y, Turner SD, Frierson HF Jr, Wotton D. 2018. TGF β signaling limits lineage plasticity in prostate cancer. *PLoS Genet* **14**: e1007409. doi:10.1371/journal.pgen.1007409
- Herbst A, Jurinovic V, Krebs S, Thieme SE, Blum H, Göke B, Koligs FT. 2014. Comprehensive analysis of β -catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/ β -catenin signaling. *BMC Genomics* **15**: 74. doi:10.1186/1471-2164-15-74
- Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO, Cho KR, Fearon ER. 2007. Mouse model of colonic adenoma-carcinoma progression based on somatic *Apc* inactivation. *Cancer Res* **67**: 9721–9730. doi:10.1158/0008-5472.CAN-07-2735
- Hutton JE, Wang X, Zimmerman LJ, Slebos RJ, Trenary IA, Young JD, Li M, Liebler DC. 2016. Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer. *Mol Cell Proteomics* **15**: 2924–2938. doi:10.1074/mcp.M116.058925
- Hyman CA, Bartholin L, Newfeld SJ, Wotton D. 2003. *Drosophila* TGIF proteins are transcriptional activators. *Mol Cell Biol* **23**: 9262–9274. doi:10.1128/MCB.23.24.9262-9274.2003
- Hyman-Walsh C, Bjerke GA, Wotton D. 2010. An autoinhibitory effect of the homothorax domain of Meis2. *FEBS J* **277**: 2584–2597. doi:10.1111/j.1742-4658.2010.07668.x
- Imoto I, Pimkhaokham A, Watanabe T, Saito-Ohara F, Soeda E, Inazawa J. 2000. Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. *Biochem Biophys Res Commun* **276**: 264–270. doi:10.1006/bbrc.2000.3449
- Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberger J, Chen X, Haigis K, Jegga AG, et al. 2007. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. *Genome Biol* **8**: R131. doi:10.1186/gb-2007-8-7-r131
- Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. *Cell* **87**: 159–170. doi:10.1016/S0092-8674(00)81333-1
- Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, et al. 2016. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* **44**: W90–W97. doi:10.1093/nar/gkw377
- Labbé E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L. 2007. Transcriptional cooperation between the transforming growth factor- β and Wnt pathways in mammary and intestinal tumorigenesis. *Cancer Res* **67**: 75–84. doi:10.1158/0008-5472.CAN-06-2559
- Lee BK, Shen W, Lee J, Rhee C, Chung H, Kim KY, Park IH, Kim J. 2015. Tgif1 counterbalances the activity of core pluripotency factors in mouse embryonic stem cells. *Cell Rep* **13**: 52–60. doi:10.1016/j.celrep.2015.08.067
- Levy L, Hill CS. 2006. Alterations in components of the TGF- β superfamily signaling pathways in human cancer. *Cytokine Growth Factor Rev* **17**: 41–58. doi:10.1016/j.cytogfr.2005.09.009
- Lo RS, Wotton D, Massagué J. 2001. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. *EMBO J* **20**: 128–136. doi:10.1093/emboj/20.1.128
- Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**: 550. doi:10.1186/s13059-014-0550-8
- Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. 2002. *cis* elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. *J Biol Chem* **277**: 33275–33283. doi:10.1074/jbc.M204935200
- Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al. 1995. Inactivation of the type II TGF- β receptor in colon cancer cells with microsatellite instability. *Science* **268**: 1336–1338. doi:10.1126/science.7761852
- Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, et al. 2014. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. *Cell* **159**: 1603–1614. doi:10.1016/j.cell.2014.11.025
- Massagué J. 2008. TGF β in cancer. *Cell* **134**: 215–230. doi:10.1016/j.cell.2008.07.001
- Massagué J, Seoane J, Wotton D. 2005. Smad transcription factors. *Genes Dev* **19**: 2783–2810. doi:10.1101/gad.1350705
- Melhuish TA, Wotton D. 2000. The interaction of the carboxyl terminus-binding protein with the Smad corepressor TGIF is disrupted by a holoprosencephaly mutation in TGIF. *J Biol Chem* **275**: 39762–39766. doi:10.1074/jbc.C000416200
- Melhuish TA, Gallo CM, Wotton D. 2001. TGIF2 interacts with histone deacetylase 1 and represses transcription. *J Biol Chem* **276**: 32109–32114. doi:10.1074/jbc.M103377200
- Miguchi M, Hinoi T, Shimomura M, Adachi T, Saito Y, Niitsu H, Kochi M, Sada H, Sotomaru Y, Ikenoue T, et al. 2016. Gasdermin C is upregulated by inactivation of transforming growth factor β receptor type II in the presence of mutated *Apc*, promoting colorectal cancer proliferation. *PLoS One* **11**: e0166422. doi:10.1371/journal.pone.0166422
- Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. 2016. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin* **66**: 271–289. doi:10.3322/caac.21349

- Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. 2003. PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet* **34**: 267–273. doi:10.1038/ng1180
- Moser AR, Pitot HC, Dove WF. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* **247**: 322–324. doi:10.1126/science.2296722
- Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, et al. 2006. Transforming growth factor β receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by *Apc* mutation. *Cancer Res* **66**: 9837–9844. doi:10.1158/0008-5472.CAN-06-0890
- Nakakuki K, Imoto I, Pimkhaokham A, Fukuda Y, Shimada Y, Imamura M, Amagasa T, Inazawa J. 2002. Novel targets for the 18p11.3 amplification frequently observed in esophageal squamous cell carcinomas. *Carcinogenesis* **23**: 19–24. doi:10.1093/carcin/23.1.19
- Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. 1995. Loss of *Apc* heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated *Apc* gene. *Proc Natl Acad Sci* **92**: 4482–4486. doi:10.1073/pnas.92.10.4482
- Parini P, Melhuish TA, Wotton D, Larsson L, Ahmed O, Eriksson M, Pramfalk C. 2018. Overexpression of transforming growth factor β induced factor homeobox1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. *Atherosclerosis* **275**: 246–255. doi:10.1016/j.atherosclerosis.2018.06.867
- Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. 2017. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* **14**: 417–419. doi:10.1038/nmeth.4197
- Pavlova NN, Thompson CB. 2016. The emerging hallmarks of cancer metabolism. *Cell Metab* **23**: 27–47. doi:10.1016/j.cmet.2015.12.006
- Polakis P. 1995. Mutations in the APC gene and their implications for protein structure and function. *Curr Opin Genet Dev* **5**: 66–71. doi:10.1016/S0959-437X(95)90055-1
- Powers SE, Taniguchi K, Yen W, Melhuish TA, Shen J, Walsh CA, Sutherland AE, Wotton D. 2010. Tgif1 and Tgif2 regulate Nodal signaling and are required for gastrulation. *Development* **137**: 249–259. doi:10.1242/dev.040782
- Sancho E, Batlle E, Clevers H. 2004. Signaling pathways in intestinal development and cancer. *Annu Rev Cell Dev Biol* **20**: 695–723. doi:10.1146/annurev.cellbio.20.010403.092805
- Satoh K, Yachida S, Sugimoto M, Oshima M, Nakagawa T, Akamatsu S, Tabata S, Saitoh K, Kato K, Sato S, et al. 2017. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. *Proc Natl Acad Sci* **114**: E7697–E7706. doi:10.1073/pnas.1710366114
- Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, et al. 2015. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. *Cancer Cell* **27**: 57–71. doi:10.1016/j.ccell.2014.12.002
- Segditsas S, Tomlinson I. 2006. Colorectal cancer and genetic alterations in the Wnt pathway. *Oncogene* **25**: 7531–7537. doi:10.1038/sj.onc.1210059
- Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, Atfi A. 2004. The novel E3 ubiquitin ligase Tiull1 associates with TGIF to target Smad2 for degradation. *EMBO J* **23**: 3780–3792. doi:10.1038/sj.emboj.7600398
- Seo SR, Ferrand N, Faresse N, Prunier C, Abécassis L, Pessah M, Bourgeade MF, Atfi A. 2006. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF- β signaling. *Mol Cell* **23**: 547–559. doi:10.1016/j.molcel.2006.06.018
- Sharma V, Antonacopoulou AG, Tanaka S, Panoutsopoulos AA, Bravou V, Kalofonos HP, Episkopou V. 2011. Enhancement of TGF- β signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer. *Cancer Res* **71**: 6438–6449. doi:10.1158/0008-5472.CAN-11-1645
- Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, Matsumoto H, Takano H, Akiyama T, Toyoshima K, et al. 1997. Rapid colorectal adenoma formation initiated by conditional targeting of the *Apc* gene. *Science* **278**: 120–123. doi:10.1126/science.278.5335.120
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci* **102**: 15545–15550. doi:10.1073/pnas.0506580102
- Taniguchi K, Anderson AE, Sutherland AE, Wotton D. 2012. Loss of Tgif function causes holoprosencephaly by disrupting the SHH signaling pathway. *PLoS Genet* **8**: e1002524. doi:10.1371/journal.pgen.1002524
- Taniguchi K, Anderson AE, Melhuish TA, Carlton AL, Manukyan A, Sutherland AE, Wotton D. 2017. Genetic and molecular analyses indicate independent effects of TGIFs on Nodal and Gli3 in neural tube patterning. *Eur J Hum Genet* **25**: 208–215. doi:10.1038/ejhg.2016.164
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. 1988. Genetic alterations during colorectal-tumor development. *N Engl J Med* **319**: 525–532. doi:10.1056/NEJM19880913190901
- Wang Y, Wang H, Gao H, Xu B, Zhai W, Li J, Zhang C. 2015. Elevated expression of TGIF is involved in lung carcinogenesis. *Tumour Biol* **36**: 9223–9231. doi:10.1007/s13277-015-3615-8
- Wang JL, Qi Z, Li YH, Zhao HM, Chen YG, Fu W. 2017. TGF β induced factor homeobox 1 promotes colorectal cancer development through activating Wnt/ β -catenin signaling. *Oncotarget* **8**: 70214–70225. doi:10.18632/oncotarget.19603
- Warburg O. 1956. On the origin of cancer cells. *Science* **123**: 309–314. doi:10.1126/science.123.3191.309
- Wotton D, Taniguchi K. 2018. Functions of TGIF homeodomain proteins and their roles in normal brain development and holoprosencephaly. *Am J Med Genet C Semin Med Genet* **178**: 128–139. doi:10.1002/ajmg.c.31612
- Wotton D, Lo RS, Lee S, Massagué J. 1999a. A Smad transcriptional corepressor. *Cell* **97**: 29–39. doi:10.1016/S0092-8674(00)80712-6
- Wotton D, Lo RS, Swaby LA, Massagué J. 1999b. Multiple modes of repression by the smad transcriptional corepressor TGIF. *J Biol Chem* **274**: 37105–37110. doi:10.1074/jbc.274.52.37105
- Zerlanko BJ, Bartholin L, Melhuish TA, Wotton D. 2012. Premature senescence and increased TGF β signaling in the absence of Tgif1. *PLoS One* **7**: e35460. doi:10.1371/journal.pone.0035460
- Zhang MZ, Ferrigno O, Wang Z, Ohnishi M, Prunier C, Levy L, Razzaque M, Horne WC, Romero D, Tzivion G, et al. 2015. TGIF governs a feed-forward network that empowers Wnt signaling to drive mammary tumorigenesis. *Cancer Cell* **27**: 547–560. doi:10.1016/j.ccell.2015.03.002

TGIF transcription factors repress acetyl CoA metabolic gene expression and promote intestinal tumor growth

Anant Shah, Tiffany A. Melhuish, Todd E. Fox, et al.

Genes Dev. 2019, **33**: originally published online February 26, 2019
Access the most recent version at doi:[10.1101/gad.320127.118](https://doi.org/10.1101/gad.320127.118)

Supplemental Material <http://genesdev.cshlp.org/content/suppl/2019/02/26/gad.320127.118.DC1>

References This article cites 70 articles, 24 of which can be accessed free at:
<http://genesdev.cshlp.org/content/33/7-8/388.full.html#ref-list-1>

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).